The effectiveness and cost evaluation of pain exposure physical therapy and conventional therapy in patients with complex regional pain syndrome type 1. Rationale and design of a randomized controlled trial by Barnhoorn, K.J. et al.
Barnhoorn et al. BMC Musculoskeletal Disorders 2012, 13:58
http://www.biomedcentral.com/1471-2474/13/58STUDY PROTOCOL Open AccessThe effectiveness and cost evaluation of pain
exposure physical therapy and conventional
therapy in patients with complex regional pain
syndrome type 1. Rationale and design of a
randomized controlled trial
Karlijn J Barnhoorn, Rob A B Oostendorp, Robert T M van Dongen, Frank P Klomp, Han Samwel,
Gert Jan van der Wilt, Eddy Adang, Hans Groenewoud, Henk van de Meent and Jan Paul M Frölke*Abstract
Background: Pain Exposure Physical Therapy is a new treatment option for patients with Complex Regional Pain
Syndrome type 1. It has been evaluated in retrospective as well as in prospective studies and proven to be safe and
possibly effective. This indicates that Pain Exposure Physical Therapy is now ready for clinical evaluation. The results of an
earlier performed pilot study with an n= 1 design, in which 20 patients with Complex Regional Pain Syndrome type 1
were treated with Pain Exposure Physical Therapy, were used for the design and power calculation of the present study.
After completion and evaluation of this phase III study, a multi-centre implementation study will be conducted.
The aim of this study is to determine whether Pain Exposure Physical Therapy can improve functional outcomes in
patients with Complex Regional Pain Syndrome type 1.
Methods/design: This study is designed as a single-blinded, randomized clinical trial. 62 patients will be randomized
with a follow-up of 9 months to demonstrate the expected treatment effect. Complex Regional Pain Syndrome type 1 is
diagnosed in accordance with the Bruehl/International Association for the Study of Pain criteria. Conventional therapy in
accordance with the Dutch guideline will be compared with Pain Exposure Physical Therapy. Primary outcome measure
is the Impairment level SumScore, restricted version.
Discussion: This is the first randomized controlled study with single blinding that has ever been planned in patients
with Complex Regional Pain Syndrome type 1 and does not focus on a single aspect of the pain syndrome but
compares treatment strategies based on completely different pathophysiological and cognitive theories.
Trial registration: Clinical trials NCT00817128; National Trial Register NTR2090Background
Complex Regional Pain Syndrome type 1 (CRPS-1) or
reflex sympathetic dystrophy (RSD) is a chronic pro-
gressive condition of an extremity characterized by a
variety of autonomic, sensory, motor and vasomotor
symptoms, usually following injury.
It describes a variety of painful conditions following injury
which appears regionally having a distal predominance of* Correspondence: J.Frolke@chir.umcn.nl
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reproduction in any medium, provided the orabnormal findings, exceeding in both magnitude and dur-
ation the expected clinical course of the inciting event [1].
It often results in impairments of neuromusculoskeletal
and movement-related functions, sensory functions and
pain, activity limitations and participation restrictions. It
shows a variable progression in the course of time.
Clinical evaluation and diagnosis of CRPS-1 are based
on clinical assessment of signs and symptoms, in accord-
ance with predetermined sets of diagnostic criteria [1].
Conventional therapy, consisting of pharmacological
pain management and pain avoidance in functional
management, has shown disappointing results in painral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Barnhoorn et al. BMC Musculoskeletal Disorders 2012, 13:58 Page 2 of 11
http://www.biomedcentral.com/1471-2474/13/58control and disabilities, and often leads to inactivity
and social disintegration. Considerable impairments
are still present over eight years after first CRPS-1
diagnosis [2].
Pain Exposure Physical Therapy (PEPT) is a new and
promising therapeutic approach [3,4]. No prospective,
randomized studies have yet been performed to evaluate
its effectiveness and efficacy compared to the conven-
tional therapy.
The CRPS outpatient department of the Radboud Uni-
versity Nijmegen Medical Centre has a long history
regarding treatment and research on CRPS-1 [2-7].
Magnitude of the problem
The incidence of CRPS-1 in the Netherlands is estimated
at around 26.2:100,000 person years and females are 3.4
times more effected than males [8]. About 22% of patients
show long-lasting symptoms and signs [2]. About 30% of
CRPS-1 patients completely omit their work during more
than one year. [9].
A vast proportion of CRPS-1 patients needs major
adaptations of their homes to be able to function with
their activity limitations and participation restrictions.
Treatment of CRPS-1
Conventional therapy
Current conventional therapy for CRPS-1 has been
consolidated in the Dutch national clinical guideline
of 2006 [10]. It is focused on the relief of symptoms
and pain with pharmacological treatment and
immobilization of the affected limb, supported by
physical therapy (e.g. by increasing control of pain,
improving skills and optimizing coping with CRPS-1)
and occupational therapy (e.g. by improving functional
abilities and independence in activities of daily living)
[6]. It results in approximately 50% reduction of dis-
ability and pain in patients with CRPS-1.
Pharmacological treatment consists of analgesics in
a step-up procedure in accordance with the WHO’s
pain ladder. Dimethylsulphoxide 50% ointment
(DMSO) is prescribed as radical scavenger for initial
treatment. In cases presenting with allodynia or
hyperalgesia, gabapentine, amitryptilin or carbamaze-
pine may be indicated. Dystonia, myoclonia and
muscle spasms may be treated with baclofen, diaze-
pam or clonazepam. Vasodilating drugs like verapamil,
ketensin and pentoxiphyllin can be prescribed for
patients presenting with cold skin. In persistent cold
CRPS-1, thoracic sympathectomy can be considered
as a treatment option [10].
Pain exposure physical therapy
PEPT is a functional form of physical therapy and
consists of a progressive-loading exercise program andmanagement of pain-avoidance behaviour without the
use of specific CRPS-1 medication or analgesics. It is
based on the assumption that behavioural and psycho-
logical factors can exacerbate pain and dysfunction and
might help maintain the condition. Patients denominate
clear treatment goals in the domains of activities and
participation.
PEPT aims to decrease kinesiophobia, pain behaviour
and learned non-use [11], and increase self-confidence in
the patients’ own physical possibilities. Living without
adaptations or living independently from caregivers,
returning to work and employment, and restarting
domestic life, self-care, mobility, hobbies and sports in a
short time are the main treatment goals. Pain relief itself
is not a primary treatment goal, and patients are
informed that an increase in pain during or after the
exercises and activities might occur. Patients are reas-
sured that an increase in pain is not a sign of injury or
tissue damage. In this respect, all conscious and uncon-
scious signs of catastrophizing and kinesiophobic behav-
iour are specified and talked through with the patient
and partner. If, despite explanation, doubt remains
about the treatment content or when patients are not
motivated to act upon instructions of the therapists, the
treatment will be ceased.
The treatment consists of progressive-loading exercises
and desensitization beyond the patients’ pain limits. To
decrease the enhanced skin sensitivity for touch and
pressure, desensitization is carried out using self-massage
and forced use of the affected arm or leg in daily activ-
ities. The progressive-loading exercises are tailored and
focused on specific body functions using standard
techniques in regular physical therapy, including passive
and active exercises to mobilize joints and muscle
stretching. During progressive loading, the physical
therapists act mainly as instructors, rewarding functional
progression and providing schedules for exercises and
activities at home. Complaining about pain is discour-
aged and it is no longer a subject of debate or a reason
to reduce the treatment intensity. Partly due to a limited
number of five sessions, PEPT is a very low-cost ap-
proach from micro- as well as macro-economic point of
view.
Rationales
The pathophysiology of CRPS-1 is not well understood.
Most of the studies that have been carried out are observa-
tional in nature, with small numbers of patients taking part
and, in most cases, without a control group. The conclu-
sions of the studies are not always direct observations, but
tend to be interpretations of the observations made by the
investigators. A distinction can be drawn between periph-
eral afferent, efferent and central mechanisms involved in
the onset and continuance of CRPS-1. So far, no clear
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isms are related to one another. Since no randomized con-
trolled trial have been published yet to validate the
different treatment strategies in patients with CRPS-1, the
rationale for a specific treatment is considered to be suffi-
ciently convincing to perform individual treatments in
patients.
Conventional therapy
It seems that a number of peripheral afferent mechan-
isms may be involved in the pathophysiology of CRPS-1.
Indications point to an inflammatory process, a neuroin-
flammatory process and tissue hypoxia. Anatomical
changes have also been seen in CRPS-1 patients. If a
(neuro)inflammatory process is involved, then immuno-
logical predisposition may be relevant. There are indica-
tions that immunological acquired and/or genetic
susceptibility may be involved in the onset of CRPS-1
[12].
(Neuro) inflammation: Disorders in high energy phos-
phate metabolism in CRPS-1 patients [13], vascular leak-
age from macromolecules [14] and significantly higher
concentrations of IL-6 and TNF alpha [15] and tryptase
in fluid from artificially produced blisters in CRPS-1
patients, indicating mast cell activity [16], point to in-
volvement of an inflammatory process in CRPS-1.
Arguments supporting the theory that neurogenic in-
flammation may play a role in triggering CRPS-1 are
higher concentrations of bradykinin, neuropeptide Y,
Calcitonin Gene-Related Peptide (CGRP) and vasoactive
intestinal peptide in patients with CRPS-1 [17] and pro-
tein extravasation induced by substance P [18].
Tissue hypoxia: Some research findings point to tissue
hypoxia in CRPS-1. Patients with the condition are more
hyperalgesic to fluids of low pH than control subjects.
This applies not only to the skin but also to the deeper
somatic structures [19]. Patients with CRPS-1 have
higher skin lactate levels than controls, suggesting a rise
in anaerobic glycolysis as a consequence of chronic tis-
sue hypoxia [20]. Capillary haemoglobin oxygenation of
the skin is normal in control individuals, lower than nor-
mal in the affected limb following surgery, and lower
than normal in both affected and control limbs of people
with CRPS-1. This suggests skin hypoxia. Reduced blood
circulation leading to under-nutrition of an affected limb
may be a factor contributing to atrophy and ulceration
[21].
Autonomic and motor dysfunctions: Autonomous
symptoms are seen in 98% of CRPS-1 patients, but often
change as the condition progresses [22]. Autonomic
functions described in connection with CRPS-1 are vaso-
motor and sudomotor changes, changes at transmitter
level and changes at receptor level. The vasoconstrictive
response of thermoregulating skin circulation is slowerin all phases of CRPS-1, suggesting sympathetic denerv-
ation, which can lead to hypersensitivity to catechola-
mines in vascular structures [23]. Motor dysfunction is
common in patients with CRPS-1. Besides muscle weak-
ness, patients can develop ‘neglect’ syndrome. The limb
feels strange (cognitive neglect), and mental and visual
attention is needed to move a limb (motor neglect) [24].Pain exposure physical therapy
Peripheral and central sensitization is a common feature
in CRPS-1 as in other neuropathic pain syndromes [25].
Various studies have shown functional changes in
patients with CRPS-1. Patients have altered central sen-
somotor response to tactile stimulation of the fingertip
[26]. Referred sensations are a feature of CRPS-1, and
this is evidence of central reorganization. Recent studies
point to a crucial roleof the central nervous system
(CNS) in the pathophysiology of CRPS-1 [27].
Not only the complex patterns of autonomic dysfunction,
but also motor and sensory symptoms imply CNS altera-
tions. Typically, active range of movement is restricted,
whereas passive movement is often possible. Plastic CNS
alterations might explain the complex sensory symptoms
(e.g. glove-stocking sensory loss, 'foreign-hand’ sensation,
mislocalization after tactile stimulation, impaired perceptual
learning ability). Central changes show both shifts in sen-
sory and motor cortex representation of the limbs in CRPS-1.
This altered reorganisation seems to be associated with a
pain perception as in phantom limb pain. Therefore, a lack
of cortical re-reorganization could be an important factor
for long term pain [28,29]. Patients with CRPS-1 show a
significant reorganization of central motor circuits, with an
increased activation of primary motor, parietal and supple-
mentary motor cortices. In addition to fMRI studies, there
are psychophysical studies showing that many patients with
CRPS-1 suffer from cognitive and motor neglect-like symp-
toms. Summarizing these results, there is growing evidence
that CNS alterations play an important role in the develop-
ment and persistence of CRPS-1 [27].
Behavioural and psychological factors can exacerbate the
pain and dysfunction in CRPS-1 and could help maintain
the condition in some patients. Effective management of
CRPS-1 requires that these aspects be addressed as part of
an integrated treatment approach [30].Current evidence
Conventional therapy
Scientific argumentation for the physical therapy ap-
proach of CRPS-1 reveals a RCT with high level quality
[6] indicating that physical therapy (in addition to med-
ical treatment) has a clinically relevant positive effect on
impairments of functions and pain. A systematic litera-
ture review [31] shows good to very good quality level II
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cing pain in adults with CRPS-1.
Analgesics are often used in clinical practice when
treating patients with CRPS-1, and their use is described
in various treatment protocols and guidelines [32-34].
The scientific support for their administration to patients
with CRPS-1 is, however, very limited. Administration of
standard analgesics appears to be based on experience in
other fields. The administration sequence in Dutch prac-
tices is based on the Dutch national clinical guideline
2006, in accordance with the WHO’s pain ladder [10].
Oral administration of analgesics is followed by intraven-
ous administration or peripheral blockade techniques
[35-39].
Dimethylsulphoxide 50% ointment (DMSO) has a
much greater beneficial impact on CRPS-1 symptoms
than placebo according to several studies [40,41]. N-
acetylcysteine, at a dose of 600 mg three times a day,
was found to have a significantly better effect on primary
cold CRPS-1 than DMSO ointment.
The anticonvulsant gabapentin causes a modest but
significant reduction in neuropathic pain symptoms in
CRPS-1 patients some weeks after the start of treatment
[42,43].
No randomized control studies have been carried out
on orally administered muscle relaxants to treat the
motor symptoms of CRPS-1 [44]. Benzodiazepines and
high doses of baclofen could have a positive effect.
Intrathecal baclofen therapy (ITB) is an invasive ther-
apy and should be limited to carefully selected patients
and, because of a high complication rate, should be con-
ducted only by physicians with considerable experience
in the implantation and care of intrathecal devices
[45,46].
Muizelaar et al. investigated the effect of calcium-
channel blockers in treating CRPS-1 [47]. They reported
that they are most effective on CRPS-1 in the acute
phase. However, the study is of moderate quality and
size, and it is primarily descriptive. The outcomes were
subjective, failing to describe the nature of the improve-
ment in patients’ conditions.
Sympathetic nerve blockade is an accepted treatment
option for CRPS-1 patients; for the upper limb blockage
of the stellate ganglion or the thoracic sympathetic
nerves, for the lower limb the lumbar sympathetic
nerves, conventionally carried out at L2 and L3. How-
ever, no randomized studies have been carried out on
CRPS-1 patients comparing the effect of sympathetic
blockades performed under local anaesthetics with valid
controls.
Pain exposure physical therapy
Regarding intensive physical therapy, including more ag-
gressive or painful exercises (desensitization, aerobics,sports and loading), we found three retrospective ana-
lyses in children with CRPS indicating that in up to 92%
of the included children, a complete recovery of symp-
toms occurred after intensive physical therapy [48-50].
Watson et al. show the effectiveness and safety of an ac-
tive “stress loading” program in 41 patients with reflex
sympathetic dystrophy, with improvement in pain,
trophic and vasomotor changes, range of motion and
grip strength [51].
Pain Exposure Physical Therapy has been evaluated in
a large case series of 106 patients with chronic CRPS-1
[4]. Ninety-four percent of the patients showed a signifi-
cantly improved function of the affected extremity, of
which 49% experienced full functional recovery. In
addition, a significant reduction in the number of symp-
toms of CRPS-1, such as pain (75% of patients
improved), use of analgesics and aids, was registered.
This case series suggests that PEPT is an effective and
safe treatment for this group of patients, who are unre-
sponsive to standard therapies.
We conducted a n= 1 study on 20 patients with acute
CRPS-1 to evaluate the safety of this approach in acute
CRPS-1 [3]. None of the patients in this case series
experienced an exacerbation of CRPS-1 during the
follow-up period of 3, 6 and 12 months. They showed a
significant improvement in functions and pain.
Aim
The aim of this study is to determine whether Pain Ex-
posure Physical Therapy (PEPT) can improve functional
outcomes in patients with CRPS-1.
Methods/design
Design of the study
This study is designed in accordance with the principles
of a single-blinded, randomized clinical trial. After
randomization to one of the two study groups, according
to a pre-fixed scheme, baseline measurements (T0) are
performed. Further measurements are taken during the
course of the treatment at three months (T1) and at the
end of the treatment at six months (T2). Follow up is at
nine months (T3) after inclusion. Patients will undergo
complete assessments at all time points.
Investigators performing the measurements will be
blinded for the treatment group. Patients will be carefully
instructed not to violate this blinding protocol.
This study is approved by the state regional ethical
committee and is registered at www.clinicaltrials.gov
with number NCT00817128 and at www.trialregister.nl
with number NTR 2090.
Setting
All patients will be screened, randomized and treated in
our university hospital, a level 1 trauma centre in a rural
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with suspected CRPS-1 are referred to our multidiscip-
linary outpatient department annually.
Study eligibility criteria
Hospitals and general practitioners in the region of our
hospital will participate in recruitment of eligible
patients. The diagnosis CRPS-1 has to be confirmed by
Bruehl/IASP criteria (see below) and screening for eligi-
bility is between three and twenty-four months after
initial injury. This screening will take place at
the outpatient department of the Radboud University
Nijmegen Medical Centre. All patients, between 18 and
80 years old, with CRPS-1 of the upper or lower extrem-
ity will then undergo eligibility assessment.
All patients with possible underlying diagnoses
which may cause the pain syndrome will be
excluded. Impairments of the contra-lateral extrem-
ity, relapse of CRPS-1, pregnancy, lactation and prior
sympathectomy of the affected extremity are criteria
for exclusion.
All patients have to give written informed consent
prior to participation in this study. An information letter
will be provided, depending on the treatment group.
Modified research diagnostic criteria for CRPS
1. Continuing pain, disproportionate to any inciting event
2. At least one symptom in each of the four following
categories
a.Sensory: reports of hyperesthesia
b.Vasomotor: reports of temperature asymmetry
and/or skin colour changes and/or skin colour
asymmetry
c.Sudomotor/oedema: reports of oedema and/or
sweating changes and/or sweating asymmetry
d.Motor/trophic: reports of decreased range of
motion and/or motor dysfunction (weakness,
tremor, dystonia) and/or trophic changes (hair,
nail, skin)
3. At least one sign in two or more of the following
categories
a.Sensory: evidence of hyperalgesia (to pinprick)
and/or allodynia (to light touch)
b.Vasomotor: evidence of temperature asymmetry
and/or skin colour changes and/or skin colour
asymmetry
c.Sudomotor/oedema: evidence of oedema and/or
sweating changes and/or sweating asymmetry
d.Motor/trophic: evidence of decreased range of
motion and/or motor dysfunction (weakness,
tremor, dystonia) and/or trophic changes (hair,
nail, skin)
4. The presence of an initiating noxious event, or a
cause of immobilization5. Symptoms cannot be explained by other diagnoses
Sample size calculation
The sample size calculation is based on the following
finding and expectation. The improvement in the
Impairment level SumScore (ISS), restricted version
[7,52], which is the primary outcome measure, for
the conventional therapy group is 55% over one year
[2]. For the PEPT-group it is estimated to be around
80% [4]. Given an alpha of 0.05 and a power of 80%
for a one-sided Chi-square test, 62 patients are
needed when using a 1:1 randomization, 31 in the
PEPT-group and 31 in the conventional therapy
group.
Trial interventions
Conventional group
The conventional treatment of CRPS-1, based on the re-
cent Dutch guideline [10], includes pharmacological
interventions with analgesics, N-acetylcysteine, calcium
channel blocker, ketanserine and dimethylsulphoxide for
local application on the skin. In case of insufficient ef-
fect, sympathetic blockade, spinal cord stimulation and
amputation may be considered. Following the Dutch
guideline, patients in the conventional care group will
also be referred to physical therapy to exercise the ex-
tremity in a pain contingent manner.
Experimental group
The experimental treatment is PEPT, a functional
form of physical therapy combined with a cognitive-
behavioural form of treatment. It consists of a maximum
of five sessions of each 40 min. Analgesics are contra-
indicated, the experienced pain will not be treated.
Patient recruitment
Diagnosis and treatment of CRPS-1 is performed by the
multidisciplinary CRPS outpatient team, including a sur-
geon, a rehabilitation physician, a physical therapist, an
anaesthesiologist and a research nurse. Around 150 new
adult patients are visiting this outpatient clinic each year
of which 23% is diagnosed having CRPS-1 (confirmed by
Bruehl/IASP criteria) between 3 and 24 months after ini-
tial injury and without underlying diagnoses which may
be responsible for the pain syndrome [53]. This means
that around 40 patients with CRPS-1 are diagnosed each
year, who can be randomized accordingly. To increase
the amount of eligible patients, the county hospitals as
well as general practitioners in Nijmegen and surround-
ings will be asked to pre-screen and send patients with
possible CRPS-1 to our outpatient department for
screening and probable enrolment into the study. It is
expected that this strategy will increase the amount of
eligible patients. All these eligible patients will be
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prior to inclusion. Both the conventional treatment and
PEPT will be executed in the Radboud University Nij-
megen Medical Centre, with blinding of the observer
during all measurements.
Time schedule
Patients will be screened and randomized from January
2009 until June 2011. A mean of 4 patients are planned
to enrol each month once the study reaches full adhe-
sion. After complete follow-up, it will be finished in the
spring of 2012. The final report after data analysis will be
expected at the end of 2012.
Randomization
Patients will be pre-screened, based on the referral
letter sent by the county hospital or general practi-
tioner, during a multi-disciplinary session of our
team. In cases of potentially positive CRPS-1 in ac-
cordance with Bruehl/IASP criteria, these patients are
invited to undergo thorough screening and multidis-
ciplinary assessment by the same team. Patients with
manifest CRPS-1 in accordance with the research
diagnostic criteria of Bruehl/IASP, judged unani-
mously by the team, are asked to participate in the
study. They are informed about the study by the re-
search nurse and if they are interested, one week of
consideration is scheduled. During this week, an ac-
celerometer (PAM, physical activity monitor) is
mounted on the affected wrist (CRPS-1 in the upper
extremity) or affected ankle (CRPS-1 in the lower ex-
tremity) to measure the intensity of activity in T0.
After this one week of consideration, a custom made
computed randomization program is used to blindly
allocate patients to one of the two treatment groups.
The randomization program is made by an investiga-
tor with no clinical involvement in the trial.
Every patient who will be screened will specifically be
informed about the possibility to change treatment group
at any time after randomization, but preferably after hav-
ing finished the initial allocated treatment. Once the
computer randomization has been completed, patients
who are allocated to the conventional care group are
scheduled for their first treatment visit at the outpatient
department of anaesthesiology within two weeks.
Patients who are allocated to the PEPT group are sched-
uled for their first treatment at the outpatient depart-
ment of rehabilitation within two weeks.
Each randomization package contains the following
forms:
 Patient identification tabs
 Checklist hospital contacts
 Outpatient chart
 All written correspondence Travel compensation forms
 Randomization form
 Informed consent
 Measurement sets (mentioned under “outcome
parameters”) for all measure moments
 Diaries (physical activity, pain score and medication
during seven days) for all measure moments
 Cost lists (e.g. doctor’s visits, medical costs) for all
measure moments
 Questionnaires (mentioned under “outcome
parameters”) for all measure moments
 PAM scoring list
 PAM result list
Blinding procedure
All measurements taken in both treatment groups
during the course of this study are carried out by an
experienced research nurse who underwent extensive
measurement instructions, training and supervision
before she was considered qualified to perform all
measurements. She is blinded for the treatment group
in all patients. In order to maintain this blindness, we
thoroughly instruct all patients not to violate her
blindness. To further guarantee her blindness, we in-
struct her to put a small amount of menthol ointment
on her upper lip during each measurement session.
This prevents her from smelling the garlic odour of
DMSO ointment, which is part of the conventional
treatment.
Outcome parameters
Primary outcome measures
The primary outcome measure is the Impairment level
SumScore (ISS), restricted version [7,52]. The ISS,
restricted version, consists of three measurement para-
meters (pain, active range of motion and temperature)
and four measurement instruments (Visual Analogue
Scale for Pain (VAS-P) [54], McGill Pain Questionnaire
Dutch Language Version (MPQ-DLV) [55], goniometry
of mobility of joints [56], and skin temperature) [57] and
has a range of 4 to 40 points. Beside the ISS, restricted
version, its individual components will be evaluated [52].
Secondary outcome measures
1. The Disability of the Arm, Shoulder and Hand
(DASH), a questionnaire which maps both
functions and daily activities of the upper limb
[58,59]. The Lower-Limb Tasks Questionnaire
(LLTQ) of McNair [60], a questionnaire which
focuses on physical tasks related to function of
the lower limb.
2. The fear-avoidance beliefs questionnaire (FABQ)
[61], a statement list regarding the perception on
pain and physical activities
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questionnaire SF-36 [62], which measures the patient’s
point of view regarding health
4. At function level, the muscle force measurements, as
derived from both hands and feet by a handheld
dynamometer (MicroFET) [63,64].
5. At level of activity limitations, for the legs the 10 m
walking test [65] (which measures the time walking a
certain distance) and the Timed Up and Go test
[66,67] (which measures the time from rising from a
chair, walking a restricted distance to sitting down
again).
6. Compliance and adherence: adherence to long-
term therapy is defined by the World Health
Organization as the extent to which a person’s
behaviour corresponds with agreed
recommendations from a healthcare provider
[68]. Physical activities like walking and exercises,
combined with an adequate use of medication,
aids and appliances, are essential to guarantee
success in the present study on patients with
CRPS-1. However, little is known about the level
of physical activity, the intensity of exercises and
the adherence of these patients to
recommendations from the physician and
physical therapist. Therefore, an extensive
assessment will be performed by interview (about
activities such as changing and maintaining body
positions, carrying, handling and moving objects,
walking and moving, self-care and household
tasks, and exercises), questionnaires (the Seven
Days Physical Activity Recall questionnaire (PAR)
[69,70], the International Physical Activity
Questionnaire (IPAQ) [71], the Pain
Catastrophizing Scale (PCS; a questionnaire
regarding the perception of pain) [72] and the
Pain Disability Index (PDI; a list measuring the
influence of pain complaints on daily life) [73])
and an accelerometer (PAM) [74] to monitor
compliance and adherence. The PAM will be
used as a control device for over- or under-
reporting of physical activity via questionnaires
(PAR, IPAQ). Patients will be instructed to wear
the PAM from the moment they go out of bed
in the morning until the moment they go to bed
at the end of the day. Scores for self-reported
physical activity will be combined with PAM-
scores to validate self-reported physical activity.
Self-reported adherence with PEPT will be
combined with observations of physicians and
physical therapists.
7. Quality of life will be measured with the EuroQol
(EQ-5D) [75]; this is on behalf of the economic
evaluation8. Adverse reactions will be monitored throughout the
trial using standardized Serious Adverse Event
forms, specifically regarding exacerbations of CRPS-1
signs and symptoms leading to medical consultation.
Economic analysis
This study investigates the potential efficiency of PEPT
versus conventional treatment in patients with CRPS-1
from a societal perspective. The economic evaluation is
based on the general principles of a cost-effectiveness
analysis. Primary outcome measures for the economic
evaluation are costs and quality adjusted life years
(QALYs). The ratio cost per QALY gained (ICER, incre-
mental cost effectiveness ratio) will be computed and un-
certainty will be determined using the bootstrap method
or Fieller method. Finally, a cost-effectiveness acceptabil-
ity curve will be derived that is able to evaluate efficiency
by using different thresholds (WTP, willingness to pay)
for a QALY. The impact of uncertainty surrounding de-
terministic parameters (for example cost-prices) on the
ICER will be explored using one-way sensitivity analyses
on the range of extremes. The economic evaluation is
being done alongside the clinical trial and consequently
adheres to the earlier presented design and measurement
points.
Patient outcome analysis
The effect analysis adheres to the design of a randomized
controlled trial, relevant for the economic evaluation
quality of life. Quality adjusted life years (QALYs) will be
computed (using the trapezium rule) in order to perform
a cost-utility analysis for the two alternative strategies.
For the overall quantification of health status as a single
index (utilities) we use the standard EQ-5D classification
system developed by the EuroQol Group. The EQ-5D is
one of the three widely used multi-attribute systems
available to determine health states preferences (utilities).
We chose the EQ-5D because 1) the five domains of the
EQ-5D reflect aspects that are thought to be important
for the population under consideration, 2) the system is
relatively simple to administer, 3) the sensitivity of the
instrument proved to be satisfactory, and 4) a reasonable
sound algorithm has been published to compute utilities.
Cost analysis
The cost analysis exists of two main parts. First, on pa-
tient level, volumes of care will be measured prospect-
ively using standardized Case Report Forms (CRF) and
patient-based diaries. Per treatment group, full cost-
prices will be determined using activity based costing.
Activities in both production processes are outpatient
visits and physical therapy. Medication costs constitute
of analgesics, DMSO 50%, n-acetylcysteine, gabapentine,
carbamazepine, amitriptylin, nortriptylin, baclofen, diazepam,
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patients will be estimated using an interview on a 2 months
recall basis by the researcher. The frictioncost-method will
be applied. Also travel time to therapy or outpatient clinic
and related costs will be considered, on the basis of
2 months recall.
The second part of the cost analysis consists of deter-
mining the cost prices for each volume of consumption
in order to use these for multiplying the volumes regis-
tered for each participating patient. The Dutch guide-
lines for cost analyses will be used [76]. For units of
care/resources where no guideline or standard prices are
available, real cost prices will be determined.
The potential effects on medical costs are expected to be
approximately €2802,75 per treatment in conventional
care and around €1008,50 per treatment in PEPT. Costs
based on social participation and work are not included in
these prices (see Table 1).
Statistical analysis
All measured data will be assembled in a computer data-
base and analyzed using SPSS 17.0. For all outcome vari-
ables, “effects” will be calculated at all evaluation time
points during as well as after treatment, by taking values
at T0 as reference values. Outcomes for each group will
be plotted graphically in time to study their patterns.
Linear mixed models will be used to examine possibleTable 1 Medical costs
Conventional therapy (CBO 200
Medical costs
Outpatient department
(first visit)
1 time
Outpatient department
(succeeding visits)
6 times
Physical therapy
(first session)
1 time
Physical therapy
(succeeding sessions)
25 times
Travel expenses 33 times
Other medical costs
Analgesics in accordance with
WHO-standard
(until step 2)
6 months NSAID
3 months tramadol
Paracetamol
DMSO 50% 3 months
n-acetylcysteïne
Gabapentine
Carbamazepine
Amitriptyline/Nortriptyline
6 months á €80
6 months à €15
6 months à €5
Miscellaneous
Baclofen; Diazepam; Clonazepam 6 months à €13 x 0.1
Vasoactive agents 6 months à €9 x 0.4
Sympathetic block
(per treatment)
€125 x 0.2
Total costs per patient per yeardifferences over the course of time and to find out if
these differences between treatment groups can be con-
sidered as statistical significant. For the level of signifi-
cance alpha = 0.05 will be used. As the difference
between groups in ISS, restricted version, is expected to be
around 25%, we take this as a minimal clinically important
difference (MCID) in effect between groups between T0
(intake) and T3 (follow-up) for the primary outcomes.
For the secondary outcomes, even as for cost differ-
ences, explorative tests will be used (Wilcoxon). Two
analyses will be performed: an intention-to-treat analysis
(ITT) and a per-protocol analysis (PP). In the ITT ana-
lysis, outcomes of all the participants will be used for the
group they are originally assigned to. In the PP analysis,
outcomes of protocol violators will be ignored.
Discussion
Clinical trials on the treatment of patients with
CRPS-1 are scarce due to deficiency and controversy
in objective diagnostic criteria and underlying patho-
physiology. Most clinicians support an approach of
multiple interventions at different dimensions, custo-
mized to the individual patient. Therefore, only few
patients can be identified with a homogenous clinical
presentation for whom a therapeutic approach can be
standardized. Intervention trials in patients with
CRPS-1 have therefore typically been focused on a6) Euro Experimental therapy (PEPT) Euro
45 1 time 45
192 1 time 32
65 2 (1 x 2 therapists) 130
1218.75 10 (5 x 2 therapists) 487.50
740 14 times 314
150
90
n.a. n.a.
60 n.a. n.a.
200 n.a. n.a.
7 n.a. n.a.
10
25 n.a. n.a.
2802.75 1008.50
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of individual trials difficult to interpret and the com-
parison of multiple trials impossible. One of the most
important efforts to improve the level of evidence for
treatments in this field is to equalize diagnostic cri-
teria. At present, the Bruehl/IASP criteria are the
international standard to diagnose a patient with sus-
pected CRPS-1, not only for research applications but
also in clinical practice. In our outpatient department
for CRPS-1 patients, we use these criteria without
restraints ever since 2004. Clinical studies from The
Netherlands have been highly respected internationally
due to the large amounts of patients that are treated
in our country. It has to be confirmed that the diag-
nostic criteria according to Veldman, which have been
used nationwide, are no longer valid. More than 75%
of patients who are referred with positive Veldman
criteria do not have CRPS-1 according to the Bruehl/
IASP criteria [53].
Due to the evolvement in diagnosing CRPS-1, it is
possible to recruit a homogenous patient group,
which is eligible for solid prognostic studies such as
the current one.
The new and promising approach in the treatment of
CRPS-1, PEPT, has proven to be safe and possibly effect-
ive, and is now ready for clinical evaluation.
This is the first randomized controlled study with sin-
gle blinding that has ever been planned in patients with
CRPS-1 and does not focus on one single item but com-
pares treatment strategies based on completely different
pathophysiological and cognitive theories.
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